Management of Functional Vision Disorders.


Journal

Current neurology and neuroscience reports
ISSN: 1534-6293
Titre abrégé: Curr Neurol Neurosci Rep
Pays: United States
ID NLM: 100931790

Informations de publication

Date de publication:
04 2022
Historique:
accepted: 22 02 2022
pubmed: 24 3 2022
medline: 28 4 2022
entrez: 23 3 2022
Statut: ppublish

Résumé

The purpose of this review is to summarize current approaches to management of functional vision disorder (FVD). Several retrospective studies of FVD in both adults and children have shed light on the range of outcomes and the prevalence of psychosocial stressors among FVD patients. While the first line of treatment for FVD is reassurance and education, recent case reports highlight the use of additional treatment modalities including psychotherapy, hypnosis, and transcranial magnetic stimulation in specific cases. Although the epidemiology and diagnosis of functional vision disorder are well described, there is limited evidence supporting treatment modalities. Nevertheless, the majority of patients improve with conservative management including reassurance, education, and appropriate follow-up. Additional approaches such as mental health care referral can be considered in refractory cases.

Identifiants

pubmed: 35320465
doi: 10.1007/s11910-022-01191-w
pii: 10.1007/s11910-022-01191-w
pmc: PMC9159901
mid: NIHMS1809990
doi:

Types de publication

Journal Article Review Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

265-273

Subventions

Organisme : NEI NIH HHS
ID : P30 EY026877
Pays : United States

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Curr Opin Neurol. 2017 Apr;30(2):200-205
pubmed: 28141741
Postgrad Med J. 1999 Apr;75(882):201-7
pubmed: 10715758
J Neurol Sci. 2016 Feb 15;361:272-6
pubmed: 26810553
Am J Ophthalmol. 1985 Jul 15;100(1):209-13
pubmed: 4014374
Neurophysiol Clin. 2014 Oct;44(4):425-31
pubmed: 25306083
J Neuroophthalmol. 2020 Dec;40(4):527-529
pubmed: 32028454
Mov Disord. 2008 Oct 15;23(13):1882-8
pubmed: 18759366
Acta Ophthalmol. 2016 Aug;94(5):e312-6
pubmed: 26581506
Am J Ophthalmol. 2003 May;135(5):670-5
pubmed: 12719075
Pract Neurol. 2019 Apr;19(2):168-172
pubmed: 30872460
Curr Opin Neurol. 2009 Feb;22(1):41-5
pubmed: 19165954
Lancet Psychiatry. 2020 Jun;7(6):491-505
pubmed: 32445688
Curr Opin Ophthalmol. 2012 Nov;23(6):460-5
pubmed: 23047164
Eur J Ophthalmol. 2012 Mar-Apr;22(2):269-73
pubmed: 21623588
J Neuroophthalmol. 2010 Mar;30(1):26-30
pubmed: 20182202
Neurology. 2011 Aug 9;77(6):564-72
pubmed: 21795652
Arch Ophthalmol. 1983 May;101(5):729-35
pubmed: 6847460
Surv Ophthalmol. 2022 Jan-Feb;67(1):8-18
pubmed: 33737039
Psychother Psychosom. 2002 Mar-Apr;71(2):66-76
pubmed: 11844942
J Neurol Neurosurg Psychiatry. 2013 Sep;84(9):1043-6
pubmed: 23385844
Can J Ophthalmol. 1996 Oct;31(6):311-3
pubmed: 8913634
Am J Ophthalmol Case Rep. 2016 Nov 17;5:90-91
pubmed: 29503955
Cereb Cortex. 2011 Oct;21(10):2394-8
pubmed: 21368085
J AAPOS. 2004 Oct;8(5):457-61
pubmed: 15492739
Eye (Lond). 2009 Sep;23(9):1866-7
pubmed: 19648893
Eur J Ophthalmol. 1991 Jul-Sep;1(3):115-8
pubmed: 1841666
Neurology. 2010 Jun 15;74(24):1986-94
pubmed: 20548043
Handb Clin Neurol. 2017;139:329-341
pubmed: 27719853
Parkinsonism Relat Disord. 2012 Mar;18(3):247-51
pubmed: 22113131
J Korean Med Sci. 2003 Aug;18(4):581-4
pubmed: 12923337
Surv Ophthalmol. 2022 Jan-Feb;67(1):2-7
pubmed: 33338471
Parkinsonism Relat Disord. 2006 Apr;12(3):177-80
pubmed: 16364676
J Neurol Neurosurg Psychiatry. 2012 Aug;83(8):842-50
pubmed: 22661497
JAMA Neurol. 2018 Sep 1;75(9):1132-1141
pubmed: 29868890
Eye (Lond). 2017 Jul;31(7):1068-1073
pubmed: 28282066
Graefes Arch Clin Exp Ophthalmol. 2022 Apr;260(4):1307-1313
pubmed: 34633521
Neurol Clin. 1995 May;13(2):321-39
pubmed: 7643828
Am J Clin Hypn. 1971 Jan;13(3):155-61
pubmed: 5539969
Spinal Cord. 2002 Jul;40(7):327-34
pubmed: 12080460
Int J Clin Exp Hypn. 2003 Jan;51(1):29-50
pubmed: 12825917
Ophthalmology. 1986 Mar;93(3):385-90
pubmed: 3703508
Ophthalmology. 2009 Sep;116(9):1808-1813.e1
pubmed: 19643491
Ophthalmology. 2005 Oct;112(10):1821-8
pubmed: 16140382
J Neurol Neurosurg Psychiatry. 2020 Oct;91(10):1037-1045
pubmed: 32732388
J Neurol Neurosurg Psychiatry. 2021 Oct;92(10):1112-1125
pubmed: 34210802
Eye (Lond). 2000 Oct;14 Pt 5:770-2
pubmed: 11116702
Ophthalmol Clin North Am. 2004 Sep;17(3):321-8, vi
pubmed: 15337191
Neurol Clin. 2010 Aug;28(3):789-802
pubmed: 20638000
Eye (Lond). 2022 May;36(5):1111-1112
pubmed: 34193984
J Neurol Phys Ther. 2007 Mar;31(1):30-9
pubmed: 17419887
Curr Treat Options Neurol. 2011 Jun;13(3):255-66
pubmed: 21468672
Neurology. 2010 Sep 28;75(13):1166-73
pubmed: 20739647
JAMA Psychiatry. 2014 Sep;71(9):997-1005
pubmed: 24989152
Neurology. 2012 Jul 17;79(3):282-4
pubmed: 22764261
Lancet Psychiatry. 2018 Apr;5(4):307-320
pubmed: 29526521
JAMA Ophthalmol. 2013 May;131(5):573-81
pubmed: 23471505
Psychosom Med. 2011 Nov-Dec;73(9):775-88
pubmed: 22048837
J Neurol. 2020 Jul;267(7):2164-2172
pubmed: 32193596
Int Ophthalmol Clin. 2019 Summer;59(3):141-152
pubmed: 31233421
Mov Disord. 2009 Jan 15;24(1):72-6
pubmed: 18831532
Semin Neurol. 2015 Oct;35(5):557-63
pubmed: 26444401
Isr Med Assoc J. 2011 Nov;13(11):684-8
pubmed: 22279703
Arch Intern Med. 2006 Jul 24;166(14):1512-8
pubmed: 16864762

Auteurs

Ragini Phansalkar (R)

School of Medicine, Stanford University, Stanford, CA, USA.

A Juliana Lockman (AJ)

Department of Psychiatry & Behavioral Sciences, Stanford University, Stanford, CA, USA.

Surbhi Bansal (S)

Department of Ophthalmology, Stanford University, CA, Palo Alto, USA.

Heather E Moss (HE)

Department of Ophthalmology, Stanford University, CA, Palo Alto, USA. hemoss@stanford.edu.
Department of Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA. hemoss@stanford.edu.
Spencer Center for Vision Research, 2370 Watson Court MC 5353, Palo Alto, CA, 94303, USA. hemoss@stanford.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH